Supercharged donor cells target stubborn blood cancers
NCT ID NCT01087294
Summary
This study tested a new cell therapy for adults whose B-cell blood cancers (like leukemia or lymphoma) came back or never fully went away after a donor stem cell transplant. Researchers collected immune cells from the original transplant donor, genetically engineered them to better recognize and attack cancer cells, and then gave them back to the patient. The main goals were to see if this treatment was safe and if it could help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA, B-CELL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
-
National Marrow Donor Program
Minneapolis, Minnesota, 55401, United States
Conditions
Explore the condition pages connected to this study.